JT
ARQT icon

Jupiter Topco’s Arcutis Biotherapeutics ARQT Stock Holding History

Jupiter Topco’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37M Buy
+1,410,435
New +$32.9M 0.02% 504

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco's ARQT Position: Q2 2026 in Review

Jupiter Topco opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 1,410,435 shares worth $37M. The stake represents 0.02% of the portfolio and ranks #504 among its holdings.

249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jupiter Topco held 1,410,435 shares of Arcutis Biotherapeutics worth $37M as of Q2 2026.
  • Arcutis Biotherapeutics was a new Jupiter Topco position in Q2 2026.
  • Arcutis Biotherapeutics made up 0.02% of Jupiter Topco's portfolio in Q2 2026, its #504 holding.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.